Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Wyles

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
AIDS Research and Therapy|August 12, 2011
Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatmentEdward R Cachay, David L Wyles, Miguel Goicoechea, et al.
Health & Justice|August 10, 2022
A retrospective, descriptive study of hepatitis C testing, prevalence, and care continuum among adults on probationKevin F Kamis, David L Wyles, Matthew S Minturn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2011
Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trialsLynn E Taylor, Marisa Holubar, Kunling Wu, et al.
MMWR. Morbidity and Mortality Weekly Report|May 9, 2014
Early identification and linkage to care of persons with chronic hepatitis B virus infection--three U.S. sites, 2012-2014Geoff A Beckett, Gilberto Ramirez, Aaron Vanderhoff, et al.
British Journal of Clinical Pharmacology|October 28, 2019
Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334sCharles S Venuto, Yoninah S Cramer, Susan L Rosenkranz, et al.
AIDS (London, England)|May 30, 2014
High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment responseBerta Pernas, Marta Grandal, Alvaro Mena, et al.
The Journal of Infectious Diseases|May 15, 2020
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune ActivationDonald D Anthony, Mark S Sulkowski, Laura M Smeaton, et al.
Open Forum Infectious Diseases|September 12, 2022
The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured PopulationNicole D Ferrante, Craig W Newcomb, Kimberly A Forde, et al.
The Journal of Infectious Diseases|June 8, 2014
Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune responseJennifer C Lin, François Habersetzer, Maribel Rodriguez-Torres, et al.
Gastroenterology|July 27, 2016
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated CirrhosisEdward Gane, Fred Poordad, Stanley Wang, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
AIDS Research and Therapy|August 12, 2011
Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatmentEdward R Cachay, David L Wyles, Miguel Goicoechea, et al.
Health & Justice|August 10, 2022
A retrospective, descriptive study of hepatitis C testing, prevalence, and care continuum among adults on probationKevin F Kamis, David L Wyles, Matthew S Minturn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2011
Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trialsLynn E Taylor, Marisa Holubar, Kunling Wu, et al.
MMWR. Morbidity and Mortality Weekly Report|May 9, 2014
Early identification and linkage to care of persons with chronic hepatitis B virus infection--three U.S. sites, 2012-2014Geoff A Beckett, Gilberto Ramirez, Aaron Vanderhoff, et al.
British Journal of Clinical Pharmacology|October 28, 2019
Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334sCharles S Venuto, Yoninah S Cramer, Susan L Rosenkranz, et al.
AIDS (London, England)|May 30, 2014
High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment responseBerta Pernas, Marta Grandal, Alvaro Mena, et al.
The Journal of Infectious Diseases|May 15, 2020
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune ActivationDonald D Anthony, Mark S Sulkowski, Laura M Smeaton, et al.
Open Forum Infectious Diseases|September 12, 2022
The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured PopulationNicole D Ferrante, Craig W Newcomb, Kimberly A Forde, et al.
The Journal of Infectious Diseases|June 8, 2014
Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune responseJennifer C Lin, François Habersetzer, Maribel Rodriguez-Torres, et al.
Gastroenterology|July 27, 2016
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated CirrhosisEdward Gane, Fred Poordad, Stanley Wang, et al.
Pageof 8